ライフサイエンスコーパス: fasting insulin

1 nce interval, 1.03-1.14 per 1-SD increase in fasting insulin).

2 esterol, triglycerides, fasting glucose, and fasting insulin.

3 m Hg for systolic blood pressure; and 7% for fasting insulin.

4 sessment of insulin resistance (HOMA-IR) and fasting insulin.

5 waist circumference, waist to hip ratio and fasting insulin.

6 ociations with HbA1c (0.03%, -0.01 to 0.08), fasting insulin (0.00%, -0.06 to 0.07), and BMI (0.11 kg

7 [95% CI -0.01, 0.01]; p = 1.00; n = 46,186); fasting insulin (0.01 pmol/l [95% CI -0.00, 0.01,]; p =

8 lly lower circulating adiponectin and higher fasting insulin (0.02 SD; 95% CI -0.07 to 0.11; N = 29,7

9 s9939609 A allele was associated with higher fasting insulin (0.039 SD [95% CI 0.013-0.064]; P = 0.00

10 ws' milk intake = 0.00 mmol/l; -0.03, 0.03); fasting insulin (0.8%; -3.2, 5.1); ISI (0) (-0.9%; -5.1,

11 2 +/- 0.075), Hb A1c (-0.052 +/- 0.015), and fasting insulin (-0.119 +/- 0.036) (all P </= 0.02 for c

12 = -0.01, +0.04; n trials = 99), but lowered fasting insulin (-1.1 pmol/L; -1.7, -0.5; n = 90).

13 tly lowered HbA1c (-0.11%; -0.17, -0.05) and fasting insulin (-1.6 pmol/L; -2.8, -0.4).

14 ply by 0.0555]; 95% CI, -3.78 to -0.72), and fasting insulin (-2.75 muIU/mL [to convert to picomoles

15 ciations with fasting blood glucose (FG) and fasting insulin, 2-h postload glucose (PG), 2-h postload

16 d pressure, 2-hour glucose, fasting glucose, fasting insulin, 2-hour insulin, insulin sensitivity, C-

17 8 +/- 4.8 vs. 16.2 +/- 5.8 pg/mL; P = 0.01), fasting insulin (20.9 +/- 10.6 vs. 9.7 +/- 6.6 mU/mL; P

18 ely after treatment were found for levels of fasting insulin (-6.37 IU/L; P = .02), total cholesterol

19 ared with 2.8 ng/mL for placebo; P < 0.001), fasting insulin (-6.5 compared with +1.2 muU/mL for plac

20 ting glucose was 5.29 mmol/L (SD 0.66), mean fasting insulin 71.29 pmol/L (47.72), and mean HOMA2-IR

21 glucose (-0.07 mmol/l; 95% CI: -0.19, 0.05); fasting insulin (8.0%; -8.7, 27.6); ISI(0) (-6.1%; -11.3

22 ; 95% confidence interval (CI) = 0.12-0.24), fasting insulin (8.5%; 95% CI = 5.9-11.1), interleukin-6

23 iglycerides (-19.1%; P-trend < 0.001), lower fasting insulin (-9.1%; P-trend = 0.002), and lower syst

24 ith a 0.31-SD (95% CI 0.26-0.35) increase in fasting insulin, a 0.34-SD (0.30-0.38) decrease in insul

25 In addition, carriers with higher fasting insulin (above the median [17 mmol/L]) experienc

26 The outcomes were blood pressure; fasting insulin, adiponectin, glucose, and apolipoprotei

27 on molecule-1, leptin, hemoglobin A(1c), and fasting insulin (adjusted odds ratio and 95% confidence

28 scan for quantitative trait loci influencing fasting insulin among 1,505 European Americans and 1,616

29 fined grains were positively associated with fasting insulin among women (P for trend = 0.002).

30 Refined grains were associated with fasting insulin among women but not men.

31 and adiponectin in the NHS and HPFS and with fasting insulin and C-peptide levels in a nationally rep

32 t may contain positional candidate genes for fasting insulin and fasting glucose (n = 1,604 subjects)

33 ught to gain insights into the regulation of fasting insulin and fasting glucose through the use of g

34 rs35929 modified the association of uMg with fasting insulin and fat mass in a general population.

35 ith smoking initiation, higher adiposity and fasting insulin and glucose but lower blood pressure and

36 Fasting insulin and glucose concentration were measured

37 i (QTLs) that contribute to the variation in fasting insulin and glucose concentrations are discrepan

38 ined with other endpoints (Matsuda index and fasting insulin and glucose concentrations).

39 Phylloquinone intake was not associated with fasting insulin and glucose concentrations, HOMA-IR, or

40 ith or without l-arginine, resulted in lower fasting insulin and glucose levels and enhanced rates of

41 nt levels, and a dose-dependent reduction of fasting insulin and glucose levels was observed.

42 s), percentage of body fat, waist-hip ratio, fasting insulin and glucose levels, and blood pressure.

43 Fasting insulin and glucose levels, weight, body composi

44 mass, left ventricular ejection fraction, or fasting insulin and glucose levels.

45 rcumference were measured regularly, as were fasting insulin and glucose levels.

46 Initiative (WHI) participants with available fasting insulin and glucose levels.

47 -analysis approach to test associations with fasting insulin and glucose on a genome-wide scale.

48 a prospective cohort study, body habitus and fasting insulin and glucose were measured at ages 9-10 a

49 ls of plasma lipids, C-reactive protein, and fasting insulin and glucose, among 8,773 adults in the N

50 (FM), systolic and diastolic blood pressure, fasting insulin and glucose, and homeostasis model asses

51 HFD increased fasting insulin and glucose, as well as glucose intolera

52 V risks included cholesterol, triglycerides, fasting insulin and glucose, body mass index (BMI), wais

53 n by demographic and anthropometric factors, fasting insulin and glucose.

54 res of glucose homeostasis: fasting glucose, fasting insulin and glycated hemoglobin (HbA1c) were stu

55 association was largely (79.9%) explained by fasting insulin and hemoglobin A(1c) levels; after furth

56 th fasting glucose; LDFT was associated with fasting insulin and HOMA-index.

57 LC2A2, PROX1 and C2CD4B) and one influencing fasting insulin and HOMA-IR (near IGF1).

58 was significant genetic correlation between fasting insulin and HOMA-IR (rho(G) > 0.86, P < 0.05), a

59 not appreciably change the interactions for fasting insulin and HOMA-IR.

60 cose and HOMA-B and two loci associated with fasting insulin and HOMA-IR.

61 also associated with fasting plasma glucose, fasting insulin and HOMA-IR.

62 n this analysis, HCV(+) subjects had greater fasting insulin and homeostasis model assessment (HOMA)

63 etween maternal protein intake and offspring fasting insulin and homeostasis model assessment of insu

64 73x10(-11) and Pinteraction=2.48x10(-11) for fasting insulin and homeostasis model assessment of insu

65 At the end of the trial, fasting insulin and homeostasis model assessment of insu

66 ein cholesterol, fasting and 2-hour glucose, fasting insulin and homeostatic model assessment of insu

67 s with plasma markers of insulin resistance (fasting insulin and homeostatic model of insulin resista

68 ns of plasma leptin, resistin, fed-state and fasting insulin and increased expression of adipogenic t

69 ion studies informative for fasting glucose, fasting insulin and indices of beta-cell function (HOMA-

70 Further, improvements in fasting insulin and insulin resistance have also been re

71 f a CpG site within ABCG1 is associated with fasting insulin and merits further evaluation as a novel

72 atively associated with percent body fat and fasting insulin and positively correlated with IS and me

73 gher R(2), P<0.05) in predicting measures of fasting insulin and systolic and diastolic blood pressur

74 sitivity index was lower (P = 0.02), and the fasting insulin and the oral-glucose-tolerance test insu

75 Fasting insulin and triglycerides were significantly hig

76 increased diabetes risk, fasting glucose, or fasting insulin and, for diabetes, showed a trend toward

77 conditions: no intervention (ctl), overnight fasting, insulin and glucose (6 mU/g, 1 mg/g) under isof

78 GGT is associated with fasting insulin (and HOMA) to the same extent in all wom

79 th fasting glucose and HbA1c and of ALT with fasting insulin (and homeostasis model assessment of ins

80 ist-to-height ratio to risk factors (lipids, fasting insulin, and blood pressures).

81 had normalized glucose tolerance, decreased fasting insulin, and decreased adiposity.

82 .3-0.7]) adjusted for ethnicity, age, waist, fasting insulin, and early insulin release (DeltaI(0-30)

83 associated with higher plasma CRP, ferritin, fasting insulin, and Hb A1c and lower adiponectin after

84 gn were used in which fasting blood glucose, fasting insulin, and HbA1c were outcomes and antibody cl

85 centrations of fasting glucose, 2-h glucose, fasting insulin, and HbA1c; 46 368 non-cases; study cons

86 active protein (CRP), ferritin, adiponectin, fasting insulin, and hemoglobin A1c (Hb A1c).

87 correlations between measured IOP, CCT, FBS, fasting insulin, and hemoglobin A1c were null.

88 ines (leptin, adiponectin), fasting glucose, fasting insulin, and HOMA-IR values were measured at bas

89 dified genetic effects on changes in weight, fasting insulin, and homeostasis model assessment of ins

90 and increased triglycerides, 2-hour glucose, fasting insulin, and homeostatic model assessment of ins

91 A significant decrease in body weight, fasting insulin, and IGF-1 levels were observed in LAR(-

92 lycemia, improved glucose tolerance, reduced fasting insulin, and improved alpha-cell function.

93 MAN2A2 and the 1q25.3 region associated with fasting insulin, and in FCRL6, SLAMF1, APOBEC3H and the

94 increased fasting plasma glucose (FPG), A1C, fasting insulin, and insulin resistance by homeostasis m

95 Fasting blood glucose, fasting insulin, and insulin tolerance were all preserve

96 d pressure, hemoglobin A1c, fasting glucose, fasting insulin, and lipids at 3 months.

97 e insulin sensitive, as evidenced by reduced fasting insulin, and lower blood glucoses in response to

98 colorectal cancer studies directly measured fasting insulin, and none evaluated free IGF-I, or endog

99 es in weight, the insulinogenic index (IGR), fasting insulin, and proinsulin were predictive of diabe

100 The mean change in weight, fasting insulin, and proinsulin, but not IGR, differed b

101 This meta-analysis suggests that early fasting insulin ascertainment in the general population

102 sociated SNP, rs4722551 near MIR148A, with a fasting insulin-associated SNP, rs4865796 in ARL15 (Pint

103 ed the interaction of triglyceride SNPs with fasting insulin-associated SNPs, individually and collec

104 ificantly and positively associated with log fasting insulin at follow-up (beta = 0.003, 95% CI 0.000

105 six previously unknown loci associated with fasting insulin at P < 5 x 10(-8) in combined discovery

106 d 19 common genetic variants associated with fasting insulin-based measures of IR.

107 a = -0.0097, P = 0.006), insulin resistance (fasting insulin beta = -0.1467, P = 0.010; homeostasis m

108 e (beta +/- SE: -2.33 +/- 0.86%; P = 0.006), fasting insulin (beta +/- SE: -8.76 +/- 4.13%; P = 0.03)

109 he top loci associated with type 2 diabetes, fasting insulin, beta-cell function by homeostasis model

110 This was followed by an improvement of fasting insulin, blood glucose, body weight, and glucose

111 olesterol but also with lower triglycerides, fasting insulin, blood pressure, and incident diabetes i

112 Changes in fasting plasma glucose, fasting insulin, blood pressure, and total, LDL, and HDL

113 L cholesterol, fasting blood glucose, HbA1c, fasting insulin, bodyweight, waist-to-hip ratio, BMI, an

114 For example fasting insulin changed by 0% per doubling of AMH (95%CI

115 t associations for T2D, fasting glucose, and fasting insulin, comprising 65, 43, and 13 single nucleo

116 LF = -0.44 +/- 0.19 mmol/L; P < 0.001), and fasting insulin concentration (PY = -1.76 +/- 1.01 mU/mL

117 g plasma glucose concentration 83 mg/dL, and fasting insulin concentration 37 pmol/L) were used.

118 Hypercarnitinemia in the presence of a fasting insulin concentration had no effect on either of

119 The fasting insulin concentration is considered a reasonable

120 A higher fasting insulin concentration or hyperinsulinemia was si

121 Loci influencing fasting insulin concentration showed association with li

122 blood pressure (BP), insulin sensitivity (1/fasting insulin concentration), fasting glucose concentr

123 ol/L (95% CI: 0.035, 0.063-ln-pmol/L) higher fasting insulin concentration.

124 eatment; P = 0.004) and appeared to decrease fasting insulin concentrations (change: -2.2 muU/mL afte

125 ears of age were also associated with raised fasting insulin concentrations (P<0.001 for both).

126 ociated with both higher fasting glucose and fasting insulin concentrations after adjustment for pote

127 tions were positively associated with higher fasting insulin concentrations and HOMA-BCF even after a

128 at the participants in the upper one-half of fasting insulin concentrations averaged only 57% of the

129 Fasting insulin concentrations decreased by an average o

130 Fasting insulin concentrations did not mediate the effec

131 n of the highest with the lowest quantile of fasting insulin concentrations showed a pooled RR (95% C

132 who had been breastfed had marginally lower fasting insulin concentrations than did those who were f

133 At the highest doses of sirolimus, fasting insulin concentrations were high and did not inc

134 glucose concentrations were similar, whereas fasting insulin concentrations were lower after the LDD

135 The mean (SD) fasting insulin concentrations were significantly (P = 0

136 mmarize the literature on the association of fasting insulin concentrations with risk of hypertension

137 onal adjustment for systolic blood pressure, fasting insulin concentrations, diabetes, and antihypert

138 ing time control experiments, with sustained fasting insulin concentrations, the arterial baroreflex-

139 ose and leucine kinetics were measured under fasting insulin conditions and during euglycemic hyperin

140 Fasting insulin decreased (P = 0.03), and both fasting (

141 baseline with alternate-day fasting, whereas fasting insulin decreased 57 +/- 4% (P < 0.001).

142 es to the fatty acid burden that accompanies fasting, insulin deficiency, and overnutrition, response

143 The association of processed meat and fasting insulin did not reach statistical significance a

144 ifference 10.3, 95% CI 8.9 to 11.8 mmHg) and fasting insulin (% difference 145%, 95%CI 124 to 168%).

145 ess (% difference 6.0%, 95%CI 1.5 to 10.7%), fasting insulin (% difference 31%, 95%CI 22 to 40%), tri

146 ic women, i.e., in the highest fourth of the fasting insulin distribution, were similar to those obta

147 Secondary outcomes included fasting insulin, fasting plasma glucose, 2-hour plasma g

148 signed to shed light on the genetic basis of fasting insulin (FI) and IR in 927 non-diabetic African

149 of MARV with analysis of triglycerides (TG), fasting insulin (FI) and waist-to-hip ratio (WHR) in 4,7

150 trations of fasting plasma glucose (FPG) and fasting insulin (FI) as prognostic markers for successfu

151 loci that influence fasting glucose (FG) and fasting insulin (FI) levels, as identified by genome-wid

152 liver disease measures; and serum levels of fasting insulin, glucose, and cholesterol in C57BL/6 mal

153 me body weight as chow fed control mice, the fasting insulin, glucose, and hepatic triglyceride level

154 We measured fasting insulin, glucose, and lipid levels, erythrocyte

155 AMH, fasting insulin, glucose, HDLc, LDLc, triglycerides and

156 score; and glucose homoeostasis measures of fasting insulin, glucose, insulin resistance, and 2-h gl

157 d measures of anthropometry, blood pressure, fasting insulin, glucose, lipids, and NAFLD by ultrasoun

158 rol arms was determined for fasting glucose, fasting insulin, glycated hemoglobin (HbA1c), and homeos

159 ficantly interacted with the diabetes GRS on fasting insulin, glycated hemoglobin (HbA1c), the homeos

160 erol <40 mg/dl, blood pressure >130/80 mmHg, fasting insulin > or =100 pmol/liter, or impaired glucos

161 ng glucose (100-125 vs. <90 mg/dL), elevated fasting insulin (>15-20 and >20 vs. <10 muU/mL), and low

162 higher MI incidence than carriers with lower fasting insulin (hazard ratio=0.58 [0.42-0.78], P<0.001,

163 2-h glucose, A1C, BMI, waist circumference, fasting insulin, HDL cholesterol, triglycerides, and blo

164 ysteine, plasma markers of glycemic control (fasting insulin, hemoglobin A1c, C-peptide, and leptin),

165 We assessed the progress in fasting insulin, homeostasis model assessment of insulin

166 Insulin-related variables included fasting insulin, Homeostasis Model Assessment, C-peptide

167 in sensitivity phenotype associations (i.e., fasting insulin, homeostasis model assessment-insulin re

168 The decrease in fasting insulin, homeostatic model assessment of insulin

169 diabetes, hypertension, and hemoglobin A1c, fasting insulin, homeostatic model assessment of insulin

170 However, it is unclear whether fasting insulin hypersecretion is a primary driver of in

171 tomography scanning to measure VAT and serum fasting insulin, IGF-I, and IGFBP-3 measurements.

172 ated with 25.8% (95% CI: 1.0%, 58.4%) higher fasting insulin in adult life, 29.6% (5.1%, 58.4%) highe

173 sociated with higher IGF2BP2 levels and with fasting insulin in an independent genetic meta-analysis

174 cript levels were positively associated with fasting insulin in both the FHS and RS.

175 HRadjBMI GRS had a stronger association with fasting insulin in children and adolescents with overwei

176 ected a quantitative trait locus influencing fasting insulin in female subjects (logarithm of odds [L

177 riants within Tpcn2 that are associated with fasting insulin in humans.

178 nteraction and conducted linkage analysis of fasting insulin in Hypertension Genetic Epidemiology Net

179 ociation with 30' Deltainsulin (OGTT 30' min fasting insulin) in an interaction with percentage of bo

180 t)) exhibited glucose intolerance, decreased fasting insulin, increased fasting glucagon levels, and

181 me spent sedentary predicts higher levels of fasting insulin independent of the amount of time spent

182 B plasma concentrations were associated with fasting insulin, inflammation, and lipids and were signi

183 cerns were validated, including elevated non-fasting insulin (insulin resistance), and elevated angio

184 orrelations (range 0.32-0.52, P < 0.05) with fasting insulin, insulin 2 h after oral glucose challeng

185 The changes in fasting glucose, fasting insulin, insulin resistance (homeostasis model a

186 LF, but not VAT, was correlated with fasting insulin, insulin-stimulated glucose disposal, an

187 Upon fasting, insulin is lowered to remove ARF1 and kinesin f

188 nce (OR per 1 SD, 1.4; 95% CI, 1.0-2.0), and fasting insulin level (OR per 1 SD, 1.6; 95% CI, 1.2-2.1

189 ings suggest that 2 biomarkers of longevity (fasting insulin level and body temperature) are decrease

190 ne spillover (r = -0.47; P = 0.008), whereas fasting insulin level related to neuronal norepinephrine

191 igher genetically determined log-transformed fasting insulin level was associated with higher CHD ris

192 nt of insulin resistance (HOMA-IR) index, or fasting insulin level, within the lowest quartile (q1)]

193 was associated with significant increases in fasting insulin level.

194 mes stronger association in those with lower fasting insulin levels (<80 pmol/L: beta=-0.013, p=1.6x1

195 le rs16872779 (intronic) was associated with fasting insulin levels (p=0.0097).

196 h fasting glucose (R = 0.325, p = 0.001) and fasting insulin levels (rho = 0.217, p = 0.033).

197 f triglyceride-raising alleles had increased fasting insulin levels (SD 0.00 per weighted allele [95%

198 d with insulin resistance phenotypes (higher fasting insulin levels adjusted for BMI, lower HDL chole

199 glucose and 433 transcripts associated with fasting insulin levels after adjusting for age, sex, tec

200 Patients with heart failure (HF) have higher fasting insulin levels and a higher prevalence of insuli

201 Albeit not statistically significant, fasting insulin levels and HOMA of insulin resistance de

202 cose utilization, with a concomitant rise in fasting insulin levels and HOMA1-%B scores.

203 Fasting insulin levels and homeostasis model assessment

204 LF/P or LF/C rats (P <0.001) as measured by fasting insulin levels and homeostasis model assessment

205 h of pancreatic islets with mildly increased fasting insulin levels and hypoglycemia.

206 The association between fasting insulin levels and incident HF was similar for H

207 nucleotide polymorphisms and haplotypes with fasting insulin levels and insulin secretion in the MACA

208 ciation of the T at-risk allele with reduced fasting insulin levels and insulin secretion index (home

209 of rs6759676 was also associated with lower fasting insulin levels and lower HOMA insulin resistance

210 7BL/6J Slc30a8 knockout (KO) mice had normal fasting insulin levels and no change in glucose-stimulat

211 locity at baseline were associated both with fasting insulin levels and with HF; however, additional

212 1.3 rs1333049 risk allele together with high fasting insulin levels benefitted from bariatric surgery

213 -53% relative to body weight), and 60% lower fasting insulin levels compared with littermate controls

214 Median fasting insulin levels decreased with pioglitazone and i

215 , waist circumference (P = 0.03), and higher fasting insulin levels in girls (P = 0.02).

216 type 2 diabetes or raise fasting glucose or fasting insulin levels in nondiabetic individuals.

217 Fasting insulin levels were determined.

218 Fasting insulin levels were not associated with risk of

219 Genetically predicted fasting insulin levels were positively associated with c

220 Fasting insulin levels were positively associated with t

221 At 6 months, fasting insulin levels were significantly reduced from b

222 mosome 19 T2dm2 quantitative trait locus for fasting insulin levels, acting via impaired insulin secr

223 weight and systolic blood pressure, lowered fasting insulin levels, and reduced HFD-induced liver ma

224 henotype (e.g. higher waist-to-hip ratio and fasting insulin levels, but lower body fat).

225 Mice fed a HFD displayed increased fasting insulin levels, hepatosteatosis and major change

226 Thus, SINKO mice had lower fasting insulin levels, improved glucose tolerance and i

227 sulin sensitivity, associated with decreased fasting insulin levels, increased recruitment of the glu

228 between puberty timing and body mass index, fasting insulin levels, lipid levels, type 2 diabetes an

229 0a8 KO mice had reduced ( approximately 20%) fasting insulin levels, though this was not associated w

230 etes mellitus-2 locus (T2dm2), which affects fasting insulin levels, to distal chromosome 19 in a lep

231 ance, which almost perfectly correlated with fasting insulin levels, was also not associated with ris

232 4+ T-cell numbers correlated positively with fasting insulin levels.

233 iets improved lipid-related risk factors and fasting insulin levels.

234 dual component of the metabolic syndrome and fasting insulin levels.

235 b mice from beta-cell apoptosis and improves fasting insulin levels.

236 Secondary outcomes included fasting insulin-like growth factor 1, lipids, glucose, i

237 /- 0.33; DM: -0.46 +/- 0.24; P = 0.001), and fasting insulin (LM: -2.01 +/- 1.10 mIU/mL; DM: -1.16 +/

238 l, 0.06 mmol/L (-0.07 to 0.2), p = 0.37; and fasting insulin (log), -0.06 mU/L (-0.19 to 0.07), p = 0

239 No effects were seen on fasting insulin<100 pmol/L; above this, study numbers we

240 Metabolic health (e.g., HOMA-IR or fasting insulin) may be more biologically relevant and m

241 patients with type 2 diabetes, a decrease in fasting insulin (MD -7 microU/ml, 95% CI -11.5, -2.5) wa

242 : -7.6 +/- 2.1 kg; P = 0.015, time x group), fasting insulin (mean +/- SD: water: -2.84 +/- 0.77 mU/L

243 relative risk of incident HF associated with fasting insulin measured at study entry.

244 of 609 whites and 339 blacks who had BMI and fasting insulin measured twice in childhood (mean age =

245 Type I had the highest values of fasting insulin (median = 12.98 mU/mL) and HOMA IR value

246 both sexes, 5alphaR activity correlated with fasting insulin (men R = 0.53, P = 0.003; women R = 0.33

247 HOMA-IR was computed as fasting insulin (mIU/L) x fasting glucose (mmol/L)/22.5.

248 ong with the previously identified predictor fasting insulin, modifies the preventive effect of baria

249 In striking contrast, HOMA-IR ([fasting insulin (muU/mL) x fasting glucose (mmol)]/22.5)

250 d hepatic insulin resistance as reflected by fasting insulin occur in the early stages of insulin res

251 y meaningful differences in fasting glucose, fasting insulin, or measures of insulin resistance despi

252 g glucose, 2-h glucose, glycated hemoglobin, fasting insulin, or thigh intramuscular fat.

253 This analysis further indicated that higher fasting insulin (ORSD: 1.82, 95% CI 1.30-2.55) and diast

254 sulin sensitivity (P = 0.0005 to P = 0.023), fasting insulin (P = 0.022 to P = 0.033), triglycerides

255 RS was associated with a greater decrease in fasting insulin (P = 0.04), HbA1c (P = 0.0001), and HOMA

256 a thickness and borderline significance with fasting insulin (p = 0.08).

257 els of fasting glucose (P = 7.70 x 10-7) and fasting insulin (P = 4.79 x 10-6), but these association

258 ed with 2-h glucose (P for trend = 0.04) and fasting insulin (P for trend = 0.004), inversely associa

259 ortion of associations with CRP, Hb A1c, and fasting insulin (P-contribution </= 0.02 for all) but no

260 ositively associated with VF (P=3.0x10(-7)), fasting insulin (P=5.4x10(-32)), and triacylglycerols (P

261 rted not usually having breakfast had higher fasting insulin (percent difference 26.4%, 95% CI 16.6%-

262 One of these associations, fasting insulin/phosphofructokinase (PFKM), overlaps wit

263 0.01 to -0.12; P=0.01) lower log-transformed fasting insulin (pmol/L) and 21% lower odds (95% confide

264 ysiological significance of the reduction in fasting insulin produced by dietary methionine restricti

265 Adjustment for weight, fasting insulin, proinsulin, and other metabolic factors

266 AST and ALT were positively correlated with fasting insulin (r = 0.22 and r = 0.35, respectively), w

267 Individuals carrying >/=17 fasting insulin-raising alleles (5.5% population) were s

268 gy compared with >12.5% of energy) had lower fasting insulin (ratio of geometric means: 0.82; 95% CI:

269 Elevated levels of fasting insulin release and insufficient glucose-stimula

270 nsitivity was determined on the basis of the fasting insulin resistance index and with an oral-glucos

271 tradiol to sex hormone-binding globulin, the fasting insulin resistance index, and C-peptide and lept

272 gion close to the leptin locus was linked to fasting insulin response to exercise training in nondiab

273 trol of brain activity during deep sleep and fasting insulin secretion rate.

274 und significant heritability for measures of fasting insulin sensitivity and beta-cell function, for

275 independent of baseline age, sex, fat mass, fasting insulin, smoking status, and follow-up time.

276 ree nuts significantly decreased HOMA-IR and fasting insulin; there was no effect of nut consumption

277 s model assessment of insulin resistance and fasting insulin) through a systematic review and meta-an

278 Similarly, using fasting insulin to define metabolic health, metabolicall

279 here was significant evidence for linkage of fasting insulin to the short arm of chromosome 17 (logar

280 justment for age, sex, BMI, fasting glucose, fasting insulin, total triglycerides, and HDL cholestero

281 onatal 25(OH)D(3) was associated with higher fasting insulin, triglyceride, and cholesterol (in women

282 However, further adjustment for fasting insulin, triglyceride, and cholesterol levels at

283 d renal function, adjustments controlled for fasting insulin, triglyceride, and cholesterol levels.

284 nsortia data were used for metabolic traits (fasting insulin, triglyceride, total cholesterol, low-de

285 Body weight, food intake, adiposity index, fasting insulin, triglycerides and cholesterol levels we

286 sed to determine clustering of risk factors (fasting insulin, triglycerides, HDL-C, and systolic bloo

287 both) and inversely with insulin resistance (fasting insulin unadjusted, P < 0.001 for both; adjusted

288 eds of genes and DNAme sites associated with fasting insulin, waist, and body mass index, as well as

289 Each 50-pmol/L increment in fasting insulin was associated with a 25% increase in ri

290 Fasting insulin was elevated in mice infused with pregna

291 Fasting insulin was positively associated with adverse e

292 Fasting insulin was significantly higher after the dairy

293 (fasting nonesterified fatty acids [NEFAs] x fasting insulin) was calculated at baseline and after 16

294 To explore sex-specific genetic effects on fasting insulin, we tested for genotype-by-sex interacti

295 SBP, triglycerides, and fasting insulin were significantly higher and HDL-C sign

296 protein cholesterol, triglycerides, glucose, fasting insulin) were measured with the use of standard

297 higher GRS might have a greater reduction in fasting insulin when consuming a high-protein diet (P =

298 -0.23; 95% CI: -0.40, -0.06; I2 = 51.7%) and fasting insulin (WMD: -0.40 muIU/mL; 95% CI: -0.73, -0.0

299 with placebo, folate supplementation lowered fasting insulin (WMD: -13.47 pmol/L; 95% CI: -21.41, -5.

300 dipose DI was calculated as ATIS: (1/GlyRa x fasting insulin) x first-phase insulin secretion.